Patents by Inventor Carlos H. Villa

Carlos H. Villa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11629198
    Abstract: Compositions and methods are provided for loading cargoes onto red blood cells. Provided herein are novel antibodies, fragments, fusion proteins and other conjugates which specifically bind red blood cells via RHCE or Band 3.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: April 18, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carlos H. Villa, Vladimir R. Muzykantov, Donald L. Siegel, Colin Greineder
  • Publication number: 20210299272
    Abstract: Compositions comprising a dual-targeted nanoparticle having a first targeting moiety and a second targeting moiety, wherein said first targeting moiety is a red blood cell (RBC)-targeting moiety are provided. In certain embodiment, the nanoparticles are bound to RBCs ex vivo. Also provided are methods of delivering selected drugs to target organs using these compositions for treatment of disease or for diagnostic imaging.
    Type: Application
    Filed: March 31, 2021
    Publication date: September 30, 2021
    Inventors: Vladimir Muzykantov, Jacob S. Brenner, Carlos H. Villa, Laura Ferguson, Elizabeth Hood
  • Publication number: 20210230592
    Abstract: Provided herein are single wall nanotube constructs to which are convalently linked a plurality of a bifunctional chelator, a therapeutic or a diagnostic radionuclide chelated to each bifunctional chelator and a plurality of morpholino oligonucleotides conjugated to the single wall nanotube. Also provided are single wall nanotube complexes which have the morpholino oligonucleotides on the single wall nanotube constructs hybridized to other morpholino oligonucleotides. The other morpholino oligonucleotides are each conjugated to a therapeutic antibody.
    Type: Application
    Filed: January 26, 2021
    Publication date: July 29, 2021
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
  • Publication number: 20210171652
    Abstract: Compositions and methods are provided for loading cargoes onto red blood cells. Provided herein are novel antibodies, fragments, fusion proteins and other conjugates which specifically bind red blood cells via RHCE or Band 3.
    Type: Application
    Filed: December 5, 2018
    Publication date: June 10, 2021
    Inventors: Carlos H. Villa, Vladimir R. Muzykantov, Donald L. Siegel, Colin Greineder
  • Patent number: 10900037
    Abstract: Provided herein is the two component self-assembly single wall nanotube system and the single wall nanotube construct that is the second component. The two component self-assembly single wall nanotube system has a morpholino oligonucleotide with a targeting moiety followed by a single wall nanotube construct with second morpholino oligonucleotides complementary to the first morpholino oligonucleotides and one or both of a therapeutic or diagnostic payload molecule linked to the single wall nanotube construct.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: January 26, 2021
    Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
  • Publication number: 20180327742
    Abstract: Provided herein is the two component self-assembly single wall nanotube system and the single wall nanotube construct that is the second component.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 15, 2018
    Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
  • Patent number: 9976137
    Abstract: Provided herein are methods for delivering a molecule in situ to a cell and for treating a cancer via the in situ delivery. The methods comprise contacting or administering to the cell, as two separate components, a morpholino oligonucleotide comprising a targeting moiety followed by a single wall nanotube construct comprising second morpholino oligonucleotides complementary to the first morpholino oligonucleotides and one or both of a therapeutic or diagnostic payload molecule linked to the single wall nanotube construct. Upon self-assembly of a single wall nanotube complex via hybridization of the first morpholino and second complementary morpholino oligonucleotides at the cell, the payload molecule is delivered. Also provided is the two component self-assembly single wall nanotube system and the single wall nanotube construct comprising the second component.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 22, 2018
    Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
  • Publication number: 20140308203
    Abstract: Provided herein are methods for delivering a molecule in situ to a cell and for treating a cancer via the in situ delivery. The methods comprise contacting or administering to the cell, as two separate components, a morpholino oligonucleotide comprising a targeting moiety followed by a single wall nanotube construct comprising second morpholino oligonucleotides complementary to the first morpholino oligonucleotides and one or both of a therapeutic or diagnostic payload molecule linked to the single wall nanotube construct. Upon self-assembly of a single wall nanotube complex via hybridization of the first morpholino and second complementary morpholino oligonucleotides at the cell, the payload molecule is delivered. Also provided is the two component self-assembly single wall nanotube system and the single wall nanotube construct comprising the second component.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 16, 2014
    Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey